サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1695199

トランスサイレチンアミロイドーシス治療の世界市場レポート 2025年

Transthyretin Amyloidosis Treatment Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
トランスサイレチンアミロイドーシス治療の世界市場レポート 2025年
出版日: 2025年03月04日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

トランスサイレチンアミロイドーシス治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.8％で80億4,000万米ドルに成長します。予測期間の成長は、治療パイプラインの拡大、遺伝子スクリーニングの増加、希少疾患に対する世界の認識向上への取り組み、個別化医療へのアプローチ、治療へのアクセスの改善などに起因すると考えられます。予測期間における主な動向には、併用療法の出現、医薬品開発のための戦略的パートナーシップ、末梢および心臓の症状を標的とする焦点、患者教育プログラムの実施、治療ガイドラインへの実臨床エビデンスの組み込みなどがあります。

研究開発（R&D）投資の増加がトランスサイレチンアミロイドーシス治療市場成長の原動力になると予測されます。研究開発投資には、科学的知識の向上、新技術の開発、革新的製品の創出、既存プロセスの強化に割り当てられる財源が含まれます。研究開発における資金調達の強化は、トランスサイレチンアミロイドーシスの新規治療手法の発見と進歩を促進します。これらのアプローチには、先駆的な薬剤、遺伝子治療、精密医療技術が含まれ、患者により効果的で的を絞った治療の選択肢を提供しています。例えば、米国を拠点とするバイオ製薬会社であるAlnylam Pharmaceuticalsは、研究開発投資を2021年の79万2,156米ドルから2022年には88万3,015米ドルに上昇させ、11.49％の成長を示しています。このように、研究開発への投資拡大がトランスサイレチンアミロイドーシス治療市場の成長を促進すると予測されます。

高齢化人口の拡大は、トランスサイレチンアミロイドーシス治療市場の成長を大きく促進する要因になると見られています。高齢化は、出生率の低下と平均寿命の延長による年齢の中央値の上昇を特徴とする人口動態の変化を意味します。加齢はトランスサイレチンアミロイドーシス（ATTR）の実質的な危険因子であり、人口が高齢化するにつれて、この病態に関連する症例の有病率が上昇します。その結果、治療が必要な患者が増加しています。例えば、世界保健機関（WHO）の2022年10月の報告書によると、世界のどの国でも人口に占める高齢者の量と割合が急増しています。2030年には、世界の6人に1人が60歳以上になると予測されています。したがって、高齢化人口の急増がトランスサイレチンアミロイドーシス治療市場の成長の舵を切っています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界トランスサイレチンアミロイドーシス治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界のトランスサイレチンアミロイドーシス治療市場：成長率分析
  • 世界のトランスサイレチンアミロイドーシス治療市場の実績：規模と成長, 2019-2024
  • 世界のトランスサイレチンアミロイドーシス治療市場の予測：規模と成長, 2024-2029, 2034F
  • 世界トランスサイレチンアミロイドーシス治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のトランスサイレチンアミロイドーシス治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • トランスサイレチンアミロイドーシス多発神経障害（ATTR-PN）
  • トランスサイレチンアミロイドーシス心筋症（ATTR-CM）
  • 世界のトランスサイレチンアミロイドーシス治療市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
  • タファミディス
  • パティシラン
  • イノテルセン
  • その他の薬物
  • 世界のトランスサイレチンアミロイドーシス治療市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 標的療法
  • 支持療法
  • パイプラインセラピー
  • 世界のトランスサイレチンアミロイドーシス治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 専門薬局
  • 小売薬局
  • オンライン薬局
  • 世界のトランスサイレチンアミロイドーシス治療市場、トランスサイレチンアミロイドーシス多発神経障害（ATTR-PN）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 初期段階のATTR-PN
  • 上級段階ATTR-PN
  • 世界のトランスサイレチンアミロイドーシス治療市場、心筋症を伴うトランスサイレチンアミロイドーシス（ATTR-CM）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 軽度のATTR-CM
  • 中等度のATTR-CM
  • 重度のATTR-CM

第7章 地域別・国別分析

  • 世界のトランスサイレチンアミロイドーシス治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界のトランスサイレチンアミロイドーシス治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • トランスサイレチンアミロイドーシス治療市場：競合情勢
  • トランスサイレチンアミロイドーシス治療市場：企業プロファイル
    • Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
    • Abbvie Inc Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • GSK Plc
  • Novo Nordisk A/S
  • Merck & Co. Inc
  • Astellas Pharma Inc.
  • Alexion Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc
  • PTC Therapeutics
  • Ionis Pharmaceuticals
  • Prothena Corporation plc
  • BridgeBio Pharma Inc.
  • Sorrento Therapeutics Inc.
  • Intellia Therapeutics
  • Akcea Therapeutics Inc.
  • Eidos Therapeutics Inc
  • Acrotech Biopharma Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • トランスサイレチンアミロイドーシス治療市場2029：新たな機会を提供する国
  • トランスサイレチンアミロイドーシス治療市場2029：新たな機会を提供するセグメント
  • トランスサイレチンアミロイドーシス治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r29178

Transthyretin amyloidosis is a gradually progressing condition marked by the accumulation of abnormal protein deposits in the body's organs and tissues. Treatment for transthyretin amyloidosis involves various medical interventions and therapeutic strategies aimed at managing and alleviating the impacts of this condition.

The primary categories of transthyretin amyloidosis treatment include transthyretin amyloidosis with polyneuropathy (ATTR-PN) and transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-PN involves the abnormal deposition of transthyretin protein in nerves, resulting in peripheral neuropathy and other neurological symptoms. Treatment options for these conditions include drugs such as tafamidis, patisiran, inotersen, as well as targeted therapy, supportive therapy, and pipeline therapies. These treatments are made available through various distribution channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies.

The transthyretin amyloidosis treatment market research report is one of a series of new reports from The Business Research Company that provides transthyretin amyloidosis treatment market statistics, including transthyretin amyloidosis treatment industry global market size, regional shares, competitors with a transthyretin amyloidosis treatment market share, detailed transthyretin amyloidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloidosis treatment industry. This transthyretin amyloidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.52 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.

The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.04 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines.

Increased investments in research and development (R&D) are projected to be the driving force behind the growth of the transthyretin amyloidosis treatment market. R&D investments encompass financial resources allocated towards advancing scientific knowledge, developing new technologies, creating innovative products, and enhancing existing processes. Augmented funding in R&D endeavors facilitates the discovery and advancement of novel treatment methodologies for transthyretin amyloidosis. These approaches include pioneering drugs, gene therapies, and precision medicine techniques, which offer patients more effective and targeted treatment options. For instance, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, elevated its research and development investment from $792,156 in 2021 to $883,015 in 2022, indicating an 11.49% growth. Thus, the escalating investment in research and development is anticipated to propel the growth of the transthyretin amyloidosis treatment market.

The expanding demographic of the aging population is poised to be a significant driver of growth in the transthyretin amyloidosis treatment market. An aging population signifies a demographic shift characterized by an increased median age due to declining fertility rates and longer life expectancies. Age is a substantial risk factor for transthyretin amyloidosis (ATTR), and as the population ages, the prevalence of cases pertaining to this condition rises. Consequently, there is a growing pool of patients necessitating treatment. For example, according to the World Health Organization's October 2022 report, every country globally is witnessing an upsurge in both the quantity and proportion of older individuals in the population. By 2030, it's projected that 1 in 6 people worldwide will be aged 60 years or older. Hence, the burgeoning demographics of the aging population are steering the growth of the transthyretin amyloidosis treatment market.

Leading companies within the transthyretin amyloidosis treatment sector are prioritizing the development of innovative and specialized therapies, notably orphan drugs, aiming to improve patient outcomes and broaden treatment options. Orphan drugs such as Eplontersen are specifically tailored to address transthyretin amyloidosis, often receiving regulatory advantages to facilitate their development. For instance, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, obtained Food and Drug Administration (FDA) approval for a new drug application concerning Eplontersen in March 2023. Eplontersen, an experimental orphan drug, is intended for the treatment of familial transthyretin-mediated amyloid, which leads to progressive polyneuropathy. Functioning as a pharmaceutical agent, Eplontersen is designed to decrease transthyretin (TTR) protein synthesis, targeting both hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA had granted Eplontersen orphan drug designation in 2022.

In April 2024, BridgeBio Pharma, a US-based biotechnology firm, entered into a collaboration with Bayer to address transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe. As part of the agreement, Bayer will have exclusive rights to commercialize the drug, while BridgeBio will receive up to $310 million in payments and royalties. This partnership increases the likelihood of acoramidis becoming available for patients affected by this serious condition. Bayer is a Germany-based life science company.

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the transthyretin amyloidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The transthyretin amyloidosis treatment market consists of revenues earned by entities by providing biopsy, echocardiography, genetic testing, and imaging studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloidosis treatment market also includes sales of tolcapone, and diflunisal. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Transthyretin Amyloidosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on transthyretin amyloidosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for transthyretin amyloidosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The transthyretin amyloidosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN); Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
  • 2) By Drug: Tafamidis; Patisiran; Inotersen; Other Drugs
  • 3) By Therapy: Targeted Therapy; Supportive Therapy; Pipeline Therapy
  • 4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN; Advanced-Stage ATTR-PN
  • 2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM; Moderate ATTR-CM; Severe ATTR-CM
  • Companies Mentioned: Pfizer Inc; Abbvie Inc; Sanofi S.A.; Bristol Myers Squibb Company; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Transthyretin Amyloidosis Treatment Market Characteristics

3. Transthyretin Amyloidosis Treatment Market Trends And Strategies

4. Transthyretin Amyloidosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Transthyretin Amyloidosis Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Transthyretin Amyloidosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Transthyretin Amyloidosis Treatment Market Growth Rate Analysis
  • 5.4. Global Transthyretin Amyloidosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Transthyretin Amyloidosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Transthyretin Amyloidosis Treatment Total Addressable Market (TAM)

6. Transthyretin Amyloidosis Treatment Market Segmentation

  • 6.1. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN)
  • Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
  • 6.2. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tafamidis
  • Patisiran
  • Inotersen
  • Other Drugs
  • 6.3. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Targeted Therapy
  • Supportive Therapy
  • Pipeline Therapy
  • 6.4. Global Transthyretin Amyloidosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.5. Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Early-Stage ATTR-PN
  • Advanced-Stage ATTR-PN
  • 6.6. Global Transthyretin Amyloidosis Treatment Market, Sub-Segmentation Of Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mild ATTR-CM
  • Moderate ATTR-CM
  • Severe ATTR-CM

7. Transthyretin Amyloidosis Treatment Market Regional And Country Analysis

  • 7.1. Global Transthyretin Amyloidosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Transthyretin Amyloidosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Transthyretin Amyloidosis Treatment Market

  • 8.1. Asia-Pacific Transthyretin Amyloidosis Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Transthyretin Amyloidosis Treatment Market

  • 9.1. China Transthyretin Amyloidosis Treatment Market Overview
  • 9.2. China Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Transthyretin Amyloidosis Treatment Market

  • 10.1. India Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Transthyretin Amyloidosis Treatment Market

  • 11.1. Japan Transthyretin Amyloidosis Treatment Market Overview
  • 11.2. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Transthyretin Amyloidosis Treatment Market

  • 12.1. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Transthyretin Amyloidosis Treatment Market

  • 13.1. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Transthyretin Amyloidosis Treatment Market

  • 14.1. South Korea Transthyretin Amyloidosis Treatment Market Overview
  • 14.2. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Transthyretin Amyloidosis Treatment Market

  • 15.1. Western Europe Transthyretin Amyloidosis Treatment Market Overview
  • 15.2. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Transthyretin Amyloidosis Treatment Market

  • 16.1. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Transthyretin Amyloidosis Treatment Market

  • 17.1. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Transthyretin Amyloidosis Treatment Market

  • 18.1. France Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Transthyretin Amyloidosis Treatment Market

  • 19.1. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Transthyretin Amyloidosis Treatment Market

  • 20.1. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Transthyretin Amyloidosis Treatment Market

  • 21.1. Eastern Europe Transthyretin Amyloidosis Treatment Market Overview
  • 21.2. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Transthyretin Amyloidosis Treatment Market

  • 22.1. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Transthyretin Amyloidosis Treatment Market

  • 23.1. North America Transthyretin Amyloidosis Treatment Market Overview
  • 23.2. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Transthyretin Amyloidosis Treatment Market

  • 24.1. USA Transthyretin Amyloidosis Treatment Market Overview
  • 24.2. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Transthyretin Amyloidosis Treatment Market

  • 25.1. Canada Transthyretin Amyloidosis Treatment Market Overview
  • 25.2. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Transthyretin Amyloidosis Treatment Market

  • 26.1. South America Transthyretin Amyloidosis Treatment Market Overview
  • 26.2. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Transthyretin Amyloidosis Treatment Market

  • 27.1. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Transthyretin Amyloidosis Treatment Market

  • 28.1. Middle East Transthyretin Amyloidosis Treatment Market Overview
  • 28.2. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Transthyretin Amyloidosis Treatment Market

  • 29.1. Africa Transthyretin Amyloidosis Treatment Market Overview
  • 29.2. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Transthyretin Amyloidosis Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Transthyretin Amyloidosis Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Transthyretin Amyloidosis Treatment Market Competitive Landscape
  • 30.2. Transthyretin Amyloidosis Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Abbvie Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Transthyretin Amyloidosis Treatment Market Other Major And Innovative Companies

  • 31.1. GSK Plc
  • 31.2. Novo Nordisk A/S
  • 31.3. Merck & Co. Inc
  • 31.4. Astellas Pharma Inc.
  • 31.5. Alexion Pharmaceuticals Inc.
  • 31.6. Alnylam Pharmaceuticals Inc
  • 31.7. PTC Therapeutics
  • 31.8. Ionis Pharmaceuticals
  • 31.9. Prothena Corporation plc
  • 31.10. BridgeBio Pharma Inc.
  • 31.11. Sorrento Therapeutics Inc.
  • 31.12. Intellia Therapeutics
  • 31.13. Akcea Therapeutics Inc.
  • 31.14. Eidos Therapeutics Inc
  • 31.15. Acrotech Biopharma Inc

32. Global Transthyretin Amyloidosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Transthyretin Amyloidosis Treatment Market

34. Recent Developments In The Transthyretin Amyloidosis Treatment Market

35. Transthyretin Amyloidosis Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Transthyretin Amyloidosis Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Transthyretin Amyloidosis Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Transthyretin Amyloidosis Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer